MicroRNA-1296 Expression is Associated with Prognosis and Inhibits Cell Proliferation and Invasion by Wnt Signaling in Non-small Cell Lung Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Jan 4

PMID 31897178

Citations 8

Authors

Haiqing Deng

Changping Xie

Yi Ye

Zhenglong Du

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are vital regulators of non-small cell lung cancer (NSCLC) development and tumorigenesis. The aim of the present study was to explore the role of miRNA (miR)-1296 expression in NSCLC. The expression of miR-1296 was detected by reverse transcription-quantitative PCR in NSCLC tissues and matched normal tissues. The association of miR-1296 expression with clinicopathological factors of NSCLC patients was evaluated by the χ test. Prognostic value of miR-1296 expression levels in patients with NSCLC was assessed using the Kaplan-Meier method and a Cox proportional hazards model; Cell Counting Kit-8, Transwell migration and western blot assays were used to detect the association between miR-1296 and cell proliferation, invasion and Wnt signaling in NSCLC, respectively. The results of the present study demonstrated that miR-1296 expression was significantly downregulated in NSCLC tissues and cells compared to corresponding controls. Lower miR-1296 expression exhibited a significant association with lymph node metastasis and tumor-node-metastasis stage of patients with NSCLC. In addition, the survival analysis demonstrated that low miR-1296 expression predicted a poorer prognosis compared to high miR-1296 expression. Multivariate Cox analysis also demonstrated that reduced miR-1296 expression was an independent risk factor of NSCLC prognosis. Additionally, miR-1296 inhibited cell proliferation, invasion and Wnt signaling in NSCLC. Thus, the results of the present study indicated that miR-1296 expression may be a potential biomarker of NSCLC prognosis and potential target for NSCLC treatment.

Citing Articles

The effect of bta-miR-1296 on the proliferation and extracellular matrix synthesis of bovine mammary fibroblasts.

Yang Y, Yuan T, Wu R, Geng Z, Lian S, Wang J In Vitro Cell Dev Biol Anim. 2024; 60(2):183-194.

PMID: 38409638 DOI: 10.1007/s11626-024-00851-0.

Characterization of exosomal microRNAs in preterm infants fed with breast milk and infant formula.

Kim E, Song J, Le L, Kim H, Koh J, Seo Y Front Nutr. 2024; 11:1339919.

PMID: 38304545 PMC: 10830786. DOI: 10.3389/fnut.2024.1339919.

Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.

Chang F, Li J, Sun Q, Wei S, Song Y Bioengineered. 2022; 13(4):8806-8822.

PMID: 35287543 PMC: 9161884. DOI: 10.1080/21655979.2022.2053810.

microRNA-1296 Inhibits Glioma Cell Growth by Targeting ABL2.

Zhang G, Xia M, Guo J, Huang Y, Huang J, Wei K Technol Cancer Res Treat. 2021; 20:1533033821990009.

PMID: 33550941 PMC: 7876570. DOI: 10.1177/1533033821990009.

Xiaoai Jiedu Recipe suppresses hepatocellular carcinogenesis through the miR-200b-3p /Notch1 axis.

Qiu W, Wang Z, Chen R, Shi H, Ma Y, Zhou H Cancer Manag Res. 2020; 12:11121-11131.

PMID: 33173345 PMC: 7646463. DOI: 10.2147/CMAR.S269991.

References

Zhang X, Ke X, Pu Q, Yuan Y, Yang W, Luo X . MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway. Oncotarget. 2016; 7(12):14569-85. PMC: 4924736. DOI: 10.18632/oncotarget.7538. View

Shan X, Wen W, Zhu D, Yan T, Cheng W, Huang Z . miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression. PLoS One. 2017; 12(1):e0170298. PMC: 5242522. DOI: 10.1371/journal.pone.0170298. View

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

De Cos J, Sojo Gonzalez M, Montero M, Perez Calvo M, Vicente M, Hernandez Valle M . Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2008; 63(1):140-5. DOI: 10.1016/j.lungcan.2008.04.013. View

Skrzypski M, Dziadziuszko R, Jassem J . MicroRNA in lung cancer diagnostics and treatment. Mutat Res. 2011; 717(1-2):25-31. DOI: 10.1016/j.mrfmmm.2011.04.002. View

Suresh R, Ali S, Ahmad A, Philip P, Sarkar F . The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Adv Exp Med Biol. 2015; 890:57-74. DOI: 10.1007/978-3-319-24932-2_4. View

Xu Q, Liu X, Liu Z, Zhou Z, Wang Y, Tu J . MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Mol Cancer. 2017; 16(1):103. PMC: 5469159. DOI: 10.1186/s12943-017-0675-y. View

Chen G, He M, Yin Y, Yan T, Cheng W, Huang Z . miR-1296-5p decreases ERBB2 expression to inhibit the cell proliferation in ERBB2-positive breast cancer. Cancer Cell Int. 2017; 17:95. PMC: 5655974. DOI: 10.1186/s12935-017-0466-y. View

Min L, Wang F, Hu S, Chen Y, Yang J, Liang S . Aberrant microRNA-137 promoter methylation is associated with lymph node metastasis and poor clinical outcomes in non-small cell lung cancer. Oncol Lett. 2018; 15(5):7744-7750. PMC: 5934732. DOI: 10.3892/ol.2018.8273. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

12.

Zhang J, Wang T, Zhang Y, Wang H, Wu Y, Liu K . Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark. 2017; 21(4):763-768. DOI: 10.3233/CBM-170337. View

13.

Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C . MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014; 9(8):e102602. PMC: 4126682. DOI: 10.1371/journal.pone.0102602. View

14.

Stewart D . Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2013; 106(1):djt356. DOI: 10.1093/jnci/djt356. View

15.

Okuyemi O, Piccirillo J, Spitznagel E . TNM staging compared with a new clinicopathological model in predicting oral tongue squamous cell carcinoma survival. Head Neck. 2013; 36(10):1481-9. DOI: 10.1002/hed.23486. View

16.

Hwang H, Mendell J . MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007; 96 Suppl:R40-4. View

17.

Carney D, Hansen H . Non-small-cell lung cancer--stalemate or progress?. N Engl J Med. 2000; 343(17):1261-2. DOI: 10.1056/NEJM200010263431710. View

18.

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

19.

Xu X, Zhu S, Tao Z, Ye S . High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer. Cancer Med. 2017; 7(1):21-31. PMC: 5773999. DOI: 10.1002/cam4.1238. View

20.

Kanaoka R, Iinuma H, Dejima H, Sakai T, Uehara H, Matsutani N . Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer. Oncology. 2018; 94(5):311-323. DOI: 10.1159/000487006. View